Jenamicin: Uses, Side Effects, Interactions, Warnings

Introduction

Jenamicin is an aminoglycoside antibiotic used to treat serious bacterial infections. It was discovered in 1963, isolated from the bacteria Micromonospora purpurea. Jenamicin is frequently prescribed to treat gram-negative blood infections, bone infections, and endocarditis. As a bactericidal antibiotic, it works by preventing the growth and killing of bacteria.

Uses

Jenamicin is prescribed to treat a variety of serious infections, including:

• Bloodstream infections (sepsis)
• Bone and joint infections
• Endocarditis (heart valve infection)
• Urinary tract infections
• Peritonitis (abdominal infection)
• Lower respiratory tract infections

It is particularly effective against multi-drug resistant gram-negative bacteria such as Pseudomonas aeruginosa, Enterobacteriaceae, and Klebsiella.

Dosage and Administration

Jenamicin is administered intravenously (IV) or intramuscularly (IM). The dosage depends on the type and severity of the infection, as well as the patient’s age, weight, and renal function. Typical adult doses range from 3-7.5 mg/kg/day divided into 2-3 doses. Doses are adjusted based on therapeutic monitoring of peak and trough serum levels. Jenamicin may also be given topically or as a bladder irrigation for certain infections.

Side Effects and Warnings

The most serious potential side effects of jenamicin are nephrotoxicity (kidney damage) and ototoxicity (hearing loss and vestibular damage). Renal function must be closely monitored during therapy. Symptoms of ototoxicity include ringing in the ears, dizziness, and high-frequency hearing loss. Other possible adverse effects include allergic reactions, neuromuscular blockade, and local irritation at the injection site.

Drug Interactions

Jenamicin can interact with other medications, including:

• Other aminoglycosides (increased risk of toxicity)
• Loop diuretics (increased risk of ototoxicity)
• Neuromuscular blocking agents (prolonged paralysis)
• Penicillins and cephalosporins (physical incompatibility)

Mechanism of Action

Like other aminoglycosides, jenamicin binds to the 30S subunit of the bacterial ribosome, interfering with protein synthesis. This leads to misreading of the genetic code and production of nonfunctional proteins, ultimately causing bacterial cell death. Jenamicin is considered concentration-dependent, meaning higher peak levels result in greater bactericidal effects.

Resistance and Microbiology

Resistance to jenamicin can occur through various mechanisms, including enzymatic inactivation, altered uptake or efflux, and ribosomal binding site mutations. Rates of resistance vary geographically and by bacterial species. Combination therapy and antibiotic stewardship are important strategies to prevent and manage jenamicin resistance.

Pharmacology

Jenamicin is poorly absorbed orally and must be given parenterally. It is widely distributed in the body, with high concentrations in the kidneys and endolymph of the inner ear. Elimination is primarily renal, with a half-life of 2-3 hours in patients with normal renal function. Dose adjustments are necessary for renal impairment. Therapeutic drug monitoring of peak and trough levels is recommended to optimize efficacy and minimize toxicity.

Pregnancy and Breastfeeding

Jenamicin is pregnancy category D, meaning there is evidence of fetal risk based on human data. It should only be used in pregnancy if the potential benefits outweigh the risks. Jenamicin is excreted in breast milk and may cause adverse effects in nursing infants. Breastfeeding is not recommended during treatment.

Precautions and Contraindications

Jenamicin should be used with caution in patients with renal impairment, hearing disorders, neuromuscular disorders, or a history of allergic reactions to aminoglycosides. It is contraindicated in patients with hypersensitivity to jenamicin or other aminoglycosides. Baseline and periodic assessments of renal function, hearing, and vestibular function are necessary during therapy.